Scinai Immunotherapeutics (SCNI) Competitors $1.59 -0.23 (-12.64%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.59 0.00 (0.00%) As of 08/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SCNI vs. PPBT, GTBP, LIAN, VYNE, VAXX, KTTA, CDT, SPRB, ENSC, and BCTXShould you be buying Scinai Immunotherapeutics stock or one of its competitors? The main competitors of Scinai Immunotherapeutics include Purple Biotech (PPBT), GT Biopharma (GTBP), LianBio (LIAN), VYNE Therapeutics (VYNE), Vaxxinity (VAXX), Pasithea Therapeutics (KTTA), Conduit Pharmaceuticals (CDT), Spruce Biosciences (SPRB), Ensysce Biosciences (ENSC), and Briacell Therap (BCTX). These companies are all part of the "pharmaceutical products" industry. Scinai Immunotherapeutics vs. Its Competitors Purple Biotech GT Biopharma LianBio VYNE Therapeutics Vaxxinity Pasithea Therapeutics Conduit Pharmaceuticals Spruce Biosciences Ensysce Biosciences Briacell Therap Purple Biotech (NASDAQ:PPBT) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership. Do institutionals and insiders have more ownership in PPBT or SCNI? 9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, PPBT or SCNI? Purple Biotech has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500. Does the media favor PPBT or SCNI? In the previous week, Purple Biotech and Purple Biotech both had 2 articles in the media. Purple Biotech's average media sentiment score of 0.93 beat Scinai Immunotherapeutics' score of 0.43 indicating that Purple Biotech is being referred to more favorably in the media. Company Overall Sentiment Purple Biotech Positive Scinai Immunotherapeutics Neutral Is PPBT or SCNI more profitable? Scinai Immunotherapeutics' return on equity of 0.00% beat Purple Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Purple BiotechN/A -14.00% -12.52% Scinai Immunotherapeutics N/A N/A -40.60% Which has stronger valuation & earnings, PPBT or SCNI? Scinai Immunotherapeutics has higher revenue and earnings than Purple Biotech. Purple Biotech is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPurple BiotechN/AN/A-$7.24M-$0.42-5.65Scinai Immunotherapeutics$660K2.41$4.80M-$9.57-0.17 Do analysts prefer PPBT or SCNI? Purple Biotech presently has a consensus target price of $33.00, indicating a potential upside of 1,290.06%. Given Purple Biotech's stronger consensus rating and higher possible upside, research analysts clearly believe Purple Biotech is more favorable than Scinai Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Purple Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Scinai Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryScinai Immunotherapeutics beats Purple Biotech on 7 of the 13 factors compared between the two stocks. Get Scinai Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCNI vs. The Competition Export to ExcelMetricScinai ImmunotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.59M$3.15B$5.75B$9.81BDividend YieldN/A2.21%3.91%4.13%P/E Ratio-0.1720.8931.1125.06Price / Sales2.41325.81433.9099.62Price / CashN/A42.6136.7858.67Price / Book0.318.659.086.18Net Income$4.80M-$54.65M$3.26B$265.11M7 Day Performance4.61%6.56%7.38%4.22%1 Month Performance-25.70%4.82%4.21%0.77%1 Year Performance-59.02%15.81%30.29%24.69% Scinai Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCNIScinai Immunotherapeutics0.9236 of 5 stars$1.59-12.6%N/A-59.0%$1.59M$660K-0.1720Upcoming EarningsShort Interest ↑Gap DownPPBTPurple Biotech2.2314 of 5 stars$2.21-1.7%$33.00+1,392.5%N/A$5.73MN/A-5.2620GTBPGT Biopharma2.6368 of 5 stars$1.71-2.3%$11.00+543.3%-40.4%$5.60MN/A-0.308News CoverageEarnings ReportGap DownLIANLianBioN/A$0.05+2.2%N/A-81.0%$5.54MN/A-0.06110VYNEVYNE Therapeutics2.1902 of 5 stars$0.36+2.4%$6.25+1,655.6%-81.1%$5.42M$500K-0.3630News CoverageEarnings ReportShort Interest ↑Gap UpVAXXVaxxinityN/A$0.04-2.3%N/A-57.0%$5.32MN/A-0.0990KTTAPasithea Therapeutics1.4074 of 5 stars$0.71+0.7%N/A-84.9%$5.25MN/A-0.073Earnings ReportShort Interest ↓Gap UpCDTConduit Pharmaceuticals0.2132 of 5 stars$1.78+2.3%N/A-99.3%$5.23MN/A0.003Earnings ReportShort Interest ↑SPRBSpruce Biosciences2.0502 of 5 stars$9.00-1.6%$131.25+1,358.3%-73.4%$5.06M$4.91M-9.5720News CoverageNegative NewsShort Interest ↑ENSCEnsysce Biosciences0.6316 of 5 stars$2.13+1.7%N/A-66.5%$5.04M$5.21M-0.3210News CoverageEarnings ReportAnalyst RevisionBCTXBriacell Therap2.8341 of 5 stars$0.74+2.4%$32.00+4,236.0%-91.2%$5.00MN/A-0.098News CoverageStock SplitShort Interest ↓ Related Companies and Tools Related Companies Purple Biotech Alternatives GT Biopharma Alternatives LianBio Alternatives VYNE Therapeutics Alternatives Vaxxinity Alternatives Pasithea Therapeutics Alternatives Conduit Pharmaceuticals Alternatives Spruce Biosciences Alternatives Ensysce Biosciences Alternatives Briacell Therap Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCNI) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Scinai Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access